Xutao Wen, Qin Zhou, Sihan Lin, Huaming Mai, Ling Zhang
{"title":"Selenium-modified hydroxyapatite titanium coating: enhancing osteogenesis and inhibiting cancer in bone invasion by head and neck squamous cell carcinoma.","authors":"Xutao Wen, Qin Zhou, Sihan Lin, Huaming Mai, Ling Zhang","doi":"10.3389/fbioe.2025.1552661","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Head and neck squamous cell carcinoma (HNSCC) frequently invades the jaw, and surgical treatment often leads to bone defects requiring reconstruction with titanium plates. To enhance the anti-tumor and bone regeneration properties of titanium, a selenium-modified hydroxyapatite coating was developed on titanium surfaces.</p><p><strong>Methods: </strong>Selenium-modified hydroxyapatite coatings was fabricated using micro-arc oxidation (MAO). The coating properties were characterized by SEM, XPS, AFM, Contacting angle test and ICP-OES. Cell proliferation assays were performed using rBMSCs and Cal27 cells. The osteogenic potential of the materials was assessed via ALP and OCN immunofluorescence staining and quantitative polymerase chain reaction (qPCR). Apoptosis in Cal27 cells was analyzed through flow cytometry, and ROS levels in rBMSCs and Cal27 cells were measured using ROS fluorescent probes.</p><p><strong>Results: </strong>A coating was successfully formed on the surface of titanium with a porous structure via MAO. The atomic percentages of calcium, phosphorus and selenium on the coating surface were 42.47%, 45.43% and 12.3%, respectively, and the ion components could be released steadily and slowly. <i>In vitro</i>, 0.2 µg/mL selenium had toxic effects on Cal27 and promoted osteogenic differentiation of rBMSCs. PCR showed that selenium increased the expression of genes related to osteogenic differentiation of rBMSCs by 3-5 times. ROS detection found differences in intracellular ROS content between Cal27 and rBMSCs.</p><p><strong>Discussion: </strong>By incorporating selenium-modified coatings, titanium implant materials can simultaneously promote osteogenesis and inhibit tumor growth, offering a promising strategy for postoperative functional recovery in HNSCC patients.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1552661"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891246/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1552661","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Selenium-modified hydroxyapatite titanium coating: enhancing osteogenesis and inhibiting cancer in bone invasion by head and neck squamous cell carcinoma.
Introduction: Head and neck squamous cell carcinoma (HNSCC) frequently invades the jaw, and surgical treatment often leads to bone defects requiring reconstruction with titanium plates. To enhance the anti-tumor and bone regeneration properties of titanium, a selenium-modified hydroxyapatite coating was developed on titanium surfaces.
Methods: Selenium-modified hydroxyapatite coatings was fabricated using micro-arc oxidation (MAO). The coating properties were characterized by SEM, XPS, AFM, Contacting angle test and ICP-OES. Cell proliferation assays were performed using rBMSCs and Cal27 cells. The osteogenic potential of the materials was assessed via ALP and OCN immunofluorescence staining and quantitative polymerase chain reaction (qPCR). Apoptosis in Cal27 cells was analyzed through flow cytometry, and ROS levels in rBMSCs and Cal27 cells were measured using ROS fluorescent probes.
Results: A coating was successfully formed on the surface of titanium with a porous structure via MAO. The atomic percentages of calcium, phosphorus and selenium on the coating surface were 42.47%, 45.43% and 12.3%, respectively, and the ion components could be released steadily and slowly. In vitro, 0.2 µg/mL selenium had toxic effects on Cal27 and promoted osteogenic differentiation of rBMSCs. PCR showed that selenium increased the expression of genes related to osteogenic differentiation of rBMSCs by 3-5 times. ROS detection found differences in intracellular ROS content between Cal27 and rBMSCs.
Discussion: By incorporating selenium-modified coatings, titanium implant materials can simultaneously promote osteogenesis and inhibit tumor growth, offering a promising strategy for postoperative functional recovery in HNSCC patients.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
